Гемапаксан Drug photo

The description is actual on 14.01.2016

  • Latin name: Hemapaxan
  • ATH code: B01AB05
  • Active ingredient: Enoksaparin of sodium (Enoxaparin sodium)
  • Producer: Italfarmaco (Italy)


One syringe with solution for p / to introductions (volume of 0,2 ml) contains 2000 ME Anti-ha an enoksaparina of sodium.

 0.4 enters into Gemapaksan (the volume of the syringe of 0,4 ml) 4000 ME Anti-ha; Gemapaksan of 0.6 — 6000 ME Anti-ha. As an excipient it is used injekts. water.

Release form

Drug is implemented in syringes on 0.2, 0.4, 0.6 ml which are sealed in cellular packagings on 2 syringes and in cardboard boxes.

Pharmacological action

Direct anticoagulating action.

Pharmacodynamics and pharmacokinetics

Drug belongs to anticoagulants of direct action and by the nature is low-molecular heparin. (Antitrombotichesky) activity high Anti-ha and low anti-IIa activity of antithrombin is characteristic of an enoksaparin of sodium. If the doses specified for the corresponding indications are used, then the bleeding time does not increase. The mechanism of action does not influence aggregation of thrombocytes, and also process of linkng of fibrinogen with platelets (thrombocytes).

Indications to use

Gemapaksan 0.2 and 0.4 ml as prophylactic

  • drug is capable to warn venous thromboses and a thrombembolia that it is especially important at various surgical and orthopedic interventions;
  • for the prevention of venous thromboses, a thromboembolism at the patients observing a bed rest at XCH III-IV of the class NYHA, acute respiratory insufficiency, acute infections and rheumatic diseases aggravated with risk factors of venous thrombosis (treat them: the age group is more senior 75, existence of new growths, thromboses, thromboembolisms, obesity, hormonal therapy, chronic insufficiency of respiratory function).

Therapy by Gemapaksan 0.6 is shown

Prevention by Gemapaksan 0.6

Helps to warn at a hemodialysis hypercoagulation in system of extracorporal blood circulation.


  • existence of the known hypersensitivity to a sodium enoksaparin, and also to heparin;
  • aneurism of vessels in a brain or the stratified aortic aneurysm;
  • hemorrhagic stroke;
  • high risk of uncontrollable bleeding;
  • severe form of uncontrollable arterial hypertension;
  • thrombocytopenia;
  • it is not applied in pediatrics.

Use with care is possible

  • in connection with potential danger of development of a hematoma in patients with spinal and epidural anesthesia;
  • various states with the increased risk of bleedings, for example: hemophilia, hypocoagulation, thrombocytopenia, angiohemophilia and other disturbances of system of a blood coagulation; a diabetes mellitus, recent childbirth, a bacterial endocarditis, stomach ulcer or a 12-perstny gut, use of intrauterine contraception, neurologic and ophthalmologic operations, a pericardis, a pericardiac exudate, the postponed radiation therapy, insufficiency of function of kidneys or a liver, a retinopathy, recently carried out spinal puncture, severe injuries, tuberculosis, exacerbations of diseases of an urinary path or respiratory system, a vasculitis, big open wounds, arterial hypertension.

Side effects

  • petechias and ecchymomas;
  • hemorrhagic syndrome;
  • hyperemia and morbidity, skin necrosis around an injetsirovaniye;
  • hematomas;
  • symptomless and immunoallergic thrombocytopenia;
  • ricochet fibrinferments;
  • superactivity of hepatic transaminases;
  • skin or system allergic reactions.

Gemapaksan, application instruction (way and dosage)

The drug is recommended to be administered subcutaneously deeply to the area of an arterial contour in parallel with a hemodialysis. It is necessary to alternate the left or right anterolateral and posterolateral parts which are on a front abdominal wall. The needle needs to be entered perpendicularly at all length (not at an angle!) directly in thickness of skin, having clamped a fold between fingers.

Prevention of thrombosis and thromboembolism at surgically sick patients

If risk of a thromboembolism average, for example, then 2000 — 4000 ME of an enoksaparin of sodium of ml of 1 times in 24 h are recommended to operation in an abdominal cavity. In the conditions of a hospital of the general surgery the first injection is done for 2 h before operation.

If risk of a thromboembolism high (orthopedic surgery), then the recommended daily dose — 4000 ME or 6000 ME enoksaparin of sodium, the divided into 2 times, first injection – for 12 h before operation. A usual course of treatment of 7-10 days, extension to an exception of risk of thromboses and a thromboembolism is possible. So in orthopedics the daily dose 4000 ME can be applied till 5 weeks.

Prevention of thrombosis and thromboembolism to the patients observing a bed rest

The recommended daily dose 4000 ME enoksaparin of sodium of 6-14 days.

Therapy at a deep vein thrombosis

Daily dose — 150 ME on 1 kg of mass of the person or 100 ME 1 kg, divided into 2 times (mainly at the complicated thromboembolic disturbances). Therapy is carried out by 10 days in a complex with peroral anticoagulants.

Therapy at unstable stenocardia or a myocardial infarction (on an ECG there is no Q tooth)

100 ME on 1 kg of mass of the person to enter each 12 h into combinations with acetylsalicylic acid (from 100 to 325 mg a day) 2-8 days for full stabilization of the patient.

Carrying out a hemodialysis and prevention of hypercoagulation in system of extracorporal blood circulation

Daily dose — 100 ME on 1 kg of mass of the person. The drug should be administered in an arterial contour at the beginning of carrying out a hemodialysis and it for a session of 4 h at once. If, fibrinous rings are found, then in addition enter 50-100 ME on 1 kg of mass of the person.

The expressed renal failure

Demands correction of a daily dosage: if the clearance of creatinine to 30 ml a minute, then for prevention of thromboses is enough 2000 ME, for carrying out therapy — 100 ME on 1 kg of mass of the person.


It is shown in the form of bleeding.

Purpose of treatment

Apply 1 mg of protamin of sulfate, in high doses it is capable to neutralize Anti-ha Gemapaksan's activity for 60%.


If the patient has no strict indications use of drugs, then it is recommended to stop any drugs influencing a hemostasis.

The combination with antagonists of phylloquinone (vitamin K), acetylsalicylic acid, antiagregant and trombolitika, blockers of glycoprotein receptors of IIb and IIIa, valproic acid, Sulfinpyrazonum, Ketorolak, NPVP, dextrans, glucocorticosteroids, Klopidogrel, Tiklopidin is contraindicated.

Terms of sale

Appointing Gemapaksan, the doctor has to write out the recipe.

Storage conditions

  • temperature to +25 °C, it is impossible to freeze;
  • place, unavailable to children.

Period of validity

2 years not to break integrity of original packaging!

Special instructions

Not to enter intramusculary!


Coincidence on the ATH code of the 4th level:

Structural analog is drug Kleksan.


  • Gemapaksan 2000ME/0,2ml No. 6 solution for a hypodermic vvedeniyaitalfarmako of Neuter. And
  • Gemapaksan 6000ME/0,6ml No. 6 solution for a hypodermic vvedeniyaitalfarmako of Neuter. And
  • Gemapaksan 4000ME/0,4ml No. 6 solution for a hypodermic vvedeniyaitalfarmako of Neuter. And
to show still
Section: For blood
in more detail

Education: Graduated from the Nikolaev national university of V. A. Sukhomlinsky, gained the diploma of the specialist with honors as "An embryologist, a cytologist, a histologist". Also, the human physiology and animals, the teacher of biology" graduated from a magistracy majoring in ". The course on discipline "Pharmacology" is with honors passable.

Experience: Worked as the senior laboratory assistant of department of Physiology and biochemistry of the Nikolaev national university of V. A. Sukhomlinsky in 2010 - 2011.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Gemapaksan surely consult with the attending physician.